Liver metastases
Liver metastases are commonly detected in a range of malignancies including colorectal
cancer (CRC), pancreatic cancer, melanoma, lung cancer and breast cancer, although CRC …
cancer (CRC), pancreatic cancer, melanoma, lung cancer and breast cancer, although CRC …
Biomarker-guided therapy for colorectal cancer: strength in complexity
A Sveen, S Kopetz, RA Lothe - Nature Reviews Clinical Oncology, 2020 - nature.com
The number of molecularly stratified treatment options available to patients with colorectal
cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide …
cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide …
[HTML][HTML] Colorectal liver metastases: Current management and future perspectives
J Martin, A Petrillo, EC Smyth, N Shaida… - World Journal of …, 2020 - ncbi.nlm.nih.gov
The liver is the commonest site of metastatic disease for patients with colorectal cancer, with
at least 25% developing colorectal liver metastases (CRLM) during the course of their …
at least 25% developing colorectal liver metastases (CRLM) during the course of their …
[HTML][HTML] The current understanding on the impact of KRAS on colorectal cancer
M Meng, K Zhong, T Jiang, Z Liu, HY Kwan… - Biomedicine & …, 2021 - Elsevier
KRAS (kirsten rat sarcoma viral oncogene) is a member of the RAS family. KRAS mutations
are one of most dominant mutations in colorectal cancer (CRC). The impact of KRAS …
are one of most dominant mutations in colorectal cancer (CRC). The impact of KRAS …
Association of BRAF mutations with survival and recurrence in surgically treated patients with metastatic colorectal liver cancer
Importance BRAFmutations are reportedly associated with aggressive tumor biology.
However, in contrast with primary colorectal cancer, the association of V600E and non …
However, in contrast with primary colorectal cancer, the association of V600E and non …
Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases …
Background Hepatic resection is considered the optimal potentially curative treatment for
colorectal liver metastases (CRLM). Following resection, up to two-thirds of patients will …
colorectal liver metastases (CRLM). Following resection, up to two-thirds of patients will …
Genetic And Morphological Evaluation (GAME) score for patients with colorectal liver metastases
Background This study sought to develop a clinical risk score for resectable colorectal liver
metastasis (CRLM) by combining clinicopathological and clinically available biological …
metastasis (CRLM) by combining clinicopathological and clinically available biological …
Anatomical resections improve disease-free survival in patients with KRAS-mutated colorectal liver metastases
Objective: To investigate the potential clinical advantage of anatomical resection versus
nonanatomical resection for colorectal liver metastases, according to KRAS mutational …
nonanatomical resection for colorectal liver metastases, according to KRAS mutational …
Prognostic factors change over time after hepatectomy for colorectal liver metastases: a multi-institutional, international analysis of 1099 patients
Objective: To evaluate the changing impact of genetic and clinicopathologic factors on
conditional overall survival (CS) over time in patients with resectable colorectal liver …
conditional overall survival (CS) over time in patients with resectable colorectal liver …
The prognostic implications of primary colorectal tumor location on recurrence and overall survival in patients undergoing resection for colorectal liver metastasis
Background and Objectives The prognostic impact of primary colorectal cancer (CRC)
location following resection of colorectal liver metastasis (CRLM) remains largely unknown …
location following resection of colorectal liver metastasis (CRLM) remains largely unknown …